AM251
SIGMA/A6226 - >98% (HPLC), solid
Synonym: 1-
CAS Number: 183232-66-8
Empirical Formula (Hill Notation): C22H21N4OCl2I
Molecular Weight: 555.24
MDL Number: MFCD01861181
Linear Formula: C22H21N4OCl2I
Product Type: Chemical
assay | >98% (HPLC) |
color | white |
form | solid |
InChI | 1S/C22H21Cl2IN4O/c1-14-20 |
InChI key | BUZAJRPLUGXRAB-UHFFFAOYSA |
originator | Sanofi Aventis |
Quality Level | 100 |
SMILES string | Cc1c(nn(-c2ccc(Cl)cc2Cl)c |
solubility | DMSO: >10 mg/mL |
H2O: insoluble |
Application: | AM251, a CB1 cannabinoid receptor antagonist, has been used in a study to determine its interaction with hippocampal neurons to enhance spatial memory in mice. |
Biochem/physiol Actions: | AM251 is a CB1 cannabinoid receptor antagonist. |
Features and Benefits: | This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Other Notes: | Salt content may vary. |
Packaging: | 10, 50 mg in glass bottle |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-36 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | >98% (HPLC) |
UNSPSC | 12352200 |